Treatment Options for Esophageal Cancer to Improve Survival

Introduction to Esophageal Cancer Treatment

The American Joint Committee on Cancer recommends surgery as the definitive treatment of choice for early-stage esophageal cancer (Tis-T1a N0), while locally advanced disease requires multimodality therapy with preoperative chemoradiation followed by surgery for adenocarcinoma, or definitive chemoradiation alone for squamous cell carcinoma patients who demonstrate complete response 1, 2

For early-stage disease, the National Comprehensive Cancer Network suggests that surgery alone is the standard treatment, regardless of histology 3, 4, 5
The European Society for Medical Oncology recommends preoperative chemoradiation (cisplatin/5-FU with 40-50 Gy) followed by surgery as the preferred approach for adenocarcinoma 3, 6, 5, 1
The American College of Surgeons states that surgery is mandatory for adenocarcinoma even after excellent response to neoadjuvant therapy 2
For squamous cell carcinoma, the National Cancer Institute recommends definitive chemoradiation without surgery as an acceptable option for patients achieving complete clinical response 1, 2

The Society of Surgical Oncology recommends that at least 16-18 and preferably 20 lymph nodes must be dissected and examined during surgery 2
The American Society of Clinical Oncology suggests that transthoracic esophagectomy with two-field lymph node dissection is recommended for intrathoracic squamous cell carcinoma 2
The European Society of Surgical Oncology states that clear surgical margins (R0 resection) are mandatory 7, 2

The American Joint Committee on Cancer recommends that endoscopic ultrasound is mandatory for surgical candidates to evaluate T and N stage 3, 5
The National Comprehensive Cancer Network suggests that upper-aerodigestive tract endoscopy is required to evaluate synchronous head and neck primaries for squamous cell carcinoma 5, 2

The American Society of Clinical Oncology recommends that palliative chemotherapy should be offered to selected patients with good performance status 3, 6, 5, 1
The European Society for Medical Oncology states that platinum/fluoropyrimidine combinations (cisplatin/5-FU) offer higher efficacy and improved quality of life 1
The National Cancer Institute suggests that single-dose brachytherapy (12 Gy) provides better long-term relief of dysphagia with fewer complications than metal stent placement 3, 6, 5, 8